2:16cv3335 • June 9, 2016
Class Period Start
May 1, 2016
Class Period End
September 23, 2016
PSLRA Deadline
August 8, 2016
Case Allegations
10b5
Statutes of Repose
May 1, 2019
Country
United States
Court
Federal Court
Please note that for cases in the settlement stage, claims are handled by the claims administrator and NOT Levi & Korsinsky. Any information or documentation previously provided to us does not constitute submission of a claim. If you need to file a claim, check the status of a claim, or have questions regarding distribution of settlement funds, please contact the claims administrator below.
Claim Deadline
December 6, 2022
Settlement Fund
$4,000,000
Settlement Status
Disbursed
Settlement Class
All persons or entities that purchased the publicly traded securities of Immunomedics, Inc. (“Immunomedics”) from May 2, 2016, through June 24, 2016, both dates inclusive.
Claim Administrator
Strategic Claims Services
Immunomedics, Inc. Securities Litigation
c/o Strategic Claims Services
600 N. Jackson St., Ste. 205
P.O. Box 230
Media, PA 19063
+1 400-4__-____
[email protected]
Settlement Website
www.strategicclaims.net/Immunomedics/Hearing Date
January 19, 2023
Opt-out Deadline
December 29, 2022
Settlement Note
Download hereProof Of Claim
Download here
May 30, 2023
The court has approved the distribution of settlement funds to eligible class members. Investors with approved claims may receive payments from the settlement. If you have questions about your claim or payment, contact the claims administrator.
Jan 19, 2023
The court has granted final approval of the settlement. Eligible investors who submit valid claims may receive a payment once the claims review and distribution process is completed.
Oct 5, 2022
To receive your portion of the recovery (if you are eligible), you must submit this form to the claims administrator by the deadline indicated on the form itself. If you do not submit this form in time, you will not be entitled to compensation. If you have questions about how to complete the form, you should contact the claims administrator.
Oct 5, 2022
Preliminary Approval of Settlement
The court has granted preliminary approval of a proposed settlement. This means the settlement can move forward for further consideration, but it has not yet received final approval. Potential class members will generally receive notice explaining the settlement, their rights, and any deadlines for submitting a claim, objecting to the settlement, or choosing not to participate.
Apr 14, 2022
Oct 8, 2020
Jun 15, 2020
Jun 1, 2020
The court has denied the defendants' request to dismiss the lawsuit. The case can now move forward to the next stage of litigation.
Jul 10, 2019
Jul 2, 2019
After reviewing the complaint(s) filed by plaintiffs, defendants have filed a motion requesting that the court dismiss some or all of the plaintiffs' claims. In a motion to dismiss, defendants might challenge the validity of plaintiffs' claims or adequacy of plaintiffs' pleadings. Once a motion to dismiss is filed, the judge will make a decision on whether part or all of the case should be dismissed or the case can proceed as alleged.
Jun 6, 2019
A new complaint has been filed on behalf of certain investors in IMMUNOMEDICS INC. Amended complaints may contain additional facts, parties, allegations, a change in the class definition, etc.
Jun 3, 2019
A new complaint has been filed on behalf of certain investors in IMMUNOMEDICS INC. Amended complaints may contain additional facts, parties, allegations, a change in the class definition, etc.
May 30, 2019
A new complaint has been filed on behalf of certain investors in IMMUNOMEDICS INC. Amended complaints may contain additional facts, parties, allegations, a change in the class definition, etc.
Apr 24, 2019
Mar 31, 2019
The court has granted the defendants' request to dismiss the lawsuit. Depending on the court's decision, the plaintiffs may be allowed to file an updated complaint or pursue an appeal.
Jan 26, 2018
After reviewing the complaint(s) filed by plaintiffs, defendants have filed a motion requesting that the court dismiss some or all of the plaintiffs' claims. In a motion to dismiss, defendants might challenge the validity of plaintiffs' claims or adequacy of plaintiffs' pleadings. Once a motion to dismiss is filed, the judge will make a decision on whether part or all of the case should be dismissed or the case can proceed as alleged.
Feb 7, 2017
The court has appointed a lead plaintiff to represent the interests of investors in the lawsuit. The lead plaintiff works with the attorneys handling the case, helps oversee the litigation, and represents the interests of the proposed class.
Jun 9, 2016
A securities fraud class action complaint has been filed on behalf of certain investors in IMMUNOMEDICS INC.
TOP
